Drug intelligence / Profile preview

brenipatide

Development stage: Phase 3
Lead developer: Eli Lilly
Modality: Peptides
Administration: Subcutaneous

Overview

Brenipatide (LY3537031) is an investigational biologic drug developed by Eli Lilly and Company that functions as a dual agonist of the gastric inhibitory polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor. It is currently being evaluated in Phase 2 clinical trials for the treatment of uncontrolled moderate to severe asthma, where it is hypothesized to reduce airway inflammation. Administered as a once-monthly subcutaneous injection, brenipatide is also under investigation for a wide range of other conditions, including obesity, metabolic disorders, and certain neuropsychiatric conditions, with some indications reaching Phase 3 development.

Other names: brenipatide

Targets

GIPR (Gastric inhibitory polypeptide receptor)GLP1R (GLP-1R)

Beyond the preview

Go deeper on brenipatide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on brenipatide.

Explore the full profile